QuintilesIMS has teamed up with four big pharma firms to gather insights into the real-world use of oncology therapies across Europe.
Working with Bristol-Myers Squibb, Lilly, Merck KGaA and Pfizer, the pharma services provider aims to bridge the gaps and inconsistencies in current data to generate a more comprehensive view of the sector.
Currently, treatment-use information in Europe is based on historical data and so only provides a backward-looking view of the area, according to the recently-merged QuintilesIMS.
Along with its partners QuintilesIMS wants to find out how oncology products are used in each country, by which patients, in which indications and in which combinations with other drugs, and so provide greater insight into current clinical practice.
It is hoped the project will generate more timely, consistent and complete data resources for pharma and, ultimately, enable healthcare providers to make better-informed decisions on patient care in future.
Cancer is the second-highest cause of death and morbidity in Europe, with over 1.7 million deaths and three million new diagnoses every year.
